NICE Gives Thumbs Down to Simponi--For Now
This article was originally published in The Pink Sheet Daily
Executive Summary
The controversial health technology assessment agency is unconvinced of the drug's cost benefit in a crowded market, which is already well served, and concerned about its long-term safety profile.
You may also be interested in...
With Discount In Place, NICE Gives Nod To Amgen's Nplate For Bleeding Disorder
Discount scheme helps draw long-running NICE appraisal of Amgen's Nplate to a positive conclusion.
With Discount In Place, NICE Gives Nod To Amgen's Nplate For Bleeding Disorder
Discount scheme helps draw long-running NICE appraisal of Amgen's Nplate to a positive conclusion.
Evidence Insufficient To Compare Psoriatic Arthritis Drugs – AHRQ
A comparative effectiveness study on drug therapies used to treat psoriatic arthritis in adults determined that the evidence is insufficient to draw any conclusions.